{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:56:27Z","timestamp":1792688187552,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jaad.2022.11.044","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T02:20:40Z","timestamp":1669774840000},"page":"521-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids"],"prefix":"10.1016","volume":"88","author":[{"given":"Margaret Ann","family":"Kreher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Margaret B.","family":"Noland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailesh","family":"Konda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Valdes-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2022.11.044_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gde.2007.12.007","article-title":"Immune surveillance: a balance between protumor and antitumor immunity","volume":"18","author":"Ostrand-Rosenberg","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.jaad.2022.11.044_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2022.11.044_bib3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccr.2005.04.014","article-title":"De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent","volume":"7","author":"de Visser","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaad.2022.11.044_bib4","first-page":"182","article-title":"The immune system and skin cancer","volume":"810","author":"Yu","year":"2014","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.jaad.2022.11.044_bib5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2133.2011.10507.x","article-title":"Roles of the immune system in skin cancer","volume":"165","author":"Rangwala","year":"2011","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2022.11.044_bib6","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.4049\/jimmunol.170.7.3572","article-title":"Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells","volume":"170","author":"Rabinovich","year":"2003","journal-title":"J Immunol"},{"issue":"2 Pt 1","key":"10.1016\/j.jaad.2022.11.044_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0190-9622(99)70185-4","article-title":"Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens","volume":"40","author":"Jensen","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.11.044_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00002018-200023020-00002","article-title":"Post-transplant malignancy: the role of immunosuppression","volume":"23","author":"Penn","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2022.11.044_bib9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1046\/j.1365-2133.2002.04976.x","article-title":"Non-melanoma skin cancer risk in the Queensland renal transplant population","volume":"147","author":"Ramsay","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2022.11.044_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/TP.0b013e3181ec7228","article-title":"Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients","volume":"90","author":"Lott","year":"2010","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jaad.2022.11.044_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archderm.139.3.301","article-title":"Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study","volume":"139","author":"Martinez","year":"2003","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.044_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamadermatol.2015.3902","article-title":"Skin cancer risk in hematopoietic stem-cell transplant recipients compared with background population and renal transplant recipients: a population-based cohort study","volume":"152","author":"Omland","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"9103","key":"10.1016\/j.jaad.2022.11.044_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2022.11.044_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13063-020-04843-9","article-title":"Combined low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy: a randomized prospective trial in lung transplantation","volume":"22","author":"Benazzo","year":"2021","journal-title":"Trials"},{"issue":"25","key":"10.1016\/j.jaad.2022.11.044_bib15","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2022.11.044_bib16","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.3389\/ti.2022.10320","article-title":"Extracorporeal photopheresis with low-dose immunosuppression in high-risk heart transplant patients-A pilot study","volume":"35","author":"G\u00f6kler","year":"2022","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.jaad.2022.11.044_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.trre.2019.07.001","article-title":"Evidence-based practice: guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients","volume":"33","author":"Pascual","year":"2019","journal-title":"Transpl Rev (Orlando)"},{"issue":"4","key":"10.1016\/j.jaad.2022.11.044_bib18","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2020.06.051","article-title":"Navigating immunosuppression in a pandemic: a guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists","volume":"83","author":"Zahedi Niaki","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"10.1016\/j.jaad.2022.11.044_bib19","doi-asserted-by":"crossref","first-page":"11369","DOI":"10.1074\/jbc.M109.028142","article-title":"Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis","volume":"285","author":"Han","year":"2010","journal-title":"J Biol Chem"},{"issue":"7296","key":"10.1016\/j.jaad.2022.11.044_bib20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature08996","article-title":"Opposing roles for calcineurin and ATF3 in squamous skin cancer","volume":"465","author":"Wu","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2022.11.044_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/1523-1747.ep12469772","article-title":"Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in\u00a0vitro","volume":"96","author":"Dupuy","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2022.11.044_bib22","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.transproceed.2003.09.020","article-title":"Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: a potential tolerogenic effect","volume":"35","author":"Sauma","year":"2003","journal-title":"Transpl Proc"},{"issue":"9","key":"10.1016\/j.jaad.2022.11.044_bib23","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/TP.0b013e318187bab0","article-title":"Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial","volume":"86","author":"Gaber","year":"2008","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jaad.2022.11.044_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/01.TP.0000437669.93963.8E","article-title":"Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release\/MMF, tacrolimus\/MMF, and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"97","author":"Silva","year":"2014","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.044_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/ajt.13596","article-title":"Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort","volume":"16","author":"Coghill","year":"2016","journal-title":"Am J Transpl"},{"issue":"9287","key":"10.1016\/j.jaad.2022.11.044_bib26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0140-6736(01)06179-7","article-title":"Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study","volume":"358","author":"Marcil","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2022.11.044_bib27","first-page":"293","article-title":"Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review","volume":"15","author":"Soleymani","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2022.11.044_bib28","series-title":"StatPearls","article-title":"Cyclosporine","author":"Tapia","year":"2021"},{"issue":"4","key":"10.1016\/j.jaad.2022.11.044_bib29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/09546634.2011.590792","article-title":"Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology","volume":"23","author":"Muellenhoff","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jaad.2022.11.044_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM198202113060615","article-title":"Azathioprine decreases suppressor T cells in patients with multiple sclerosis","volume":"306","author":"Trotter","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2022.11.044_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009748709096717","article-title":"Modes of action of second-line agents","volume":"64","author":"Bacon","year":"1987","journal-title":"Scand J Rheumatol Suppl"},{"issue":"8","key":"10.1016\/j.jaad.2022.11.044_bib32","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jaad.2022.11.044_bib33","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1681\/ASN.2009101043","article-title":"Long-term cancer risk of immunosuppressive regimens after kidney transplantation","volume":"21","author":"Gallagher","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.jaad.2022.11.044_bib34","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/ajt.13863","article-title":"Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis","volume":"16","author":"Jiyad","year":"2016","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1016\/j.jaad.2022.11.044_bib35","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jaad.2022.11.044_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.jaad.2022.11.044_bib37","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec Claims Database Study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.jaad.2022.11.044_bib38","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2022.11.044_bib39","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.jaad.2022.11.044_bib40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.healun.2018.03.012","article-title":"Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation","volume":"37","author":"Vos","year":"2018","journal-title":"J Heart Lung Transpl"},{"issue":"8","key":"10.1016\/j.jaad.2022.11.044_bib41","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1016\/j.transproceed.2010.08.003","article-title":"Incidence and risk factors for nonmelanoma skin cancer after heart transplantation","volume":"42","author":"Molina","year":"2010","journal-title":"Transpl Proc"},{"issue":"3","key":"10.1016\/j.jaad.2022.11.044_bib42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1681\/ASN.2010040351","article-title":"The evolving role of mTOR inhibition in transplantation tolerance","volume":"22","author":"McMahon","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.jaad.2022.11.044_bib43","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3390\/ijms23031693","article-title":"Predominant role of mTOR signaling in skin diseases with therapeutic potential","volume":"23","author":"Karagianni","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jaad.2022.11.044_bib44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/TP.0b013e3182247ae2","article-title":"Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial","volume":"92","author":"Alber\u00fa","year":"2011","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jaad.2022.11.044_bib45","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1600-6143.2009.02997.x","article-title":"Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial","volume":"10","author":"Salgo","year":"2010","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1016\/j.jaad.2022.11.044_bib46","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer","volume":"12","author":"Campbell","year":"2012","journal-title":"Am J Transpl"},{"issue":"10","key":"10.1016\/j.jaad.2022.11.044_bib47","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2012.45.6376","article-title":"Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus","volume":"31","author":"Hoogendijk-van den Akker","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2022.11.044_bib48","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1432-2277.2009.01010.x","article-title":"Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients","volume":"23","author":"Euvrard","year":"2010","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.jaad.2022.11.044_bib49","first-page":"480","article-title":"Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients","volume":"12","author":"Alter","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2022.11.044_bib50","doi-asserted-by":"crossref","first-page":"7089482","DOI":"10.1155\/2019\/7089482","article-title":"Risk factors for developing nonmelanoma skin cancer after lung transplantation","volume":"2019","author":"Gr\u00e4ger","year":"2019","journal-title":"J Skin Cancer"},{"issue":"12","key":"10.1016\/j.jaad.2022.11.044_bib51","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1111\/ajt.14948","article-title":"De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: a trial-based linkage study","volume":"18","author":"Ying","year":"2018","journal-title":"Am J Transpl"},{"issue":"1","key":"10.1016\/j.jaad.2022.11.044_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0167-0115(97)01063-X","article-title":"Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures","volume":"73","author":"Franchimont","year":"1998","journal-title":"Regul Pept"},{"issue":"5","key":"10.1016\/j.jaad.2022.11.044_bib53","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1054\/bjoc.2001.1931","article-title":"Non-melanoma skin cancers and glucocorticoid therapy","volume":"85","author":"Karagas","year":"2001","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2022.11.044_bib54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6604796","article-title":"Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study","volume":"100","author":"Jensen","year":"2009","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.jaad.2022.11.044_bib55","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1468-3083.2011.04226.x","article-title":"Oral prednisone use and risk of keratinocyte carcinoma in non-transplant population. The VATTC trial","volume":"26","author":"Baibergenova","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2022.11.044_bib56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/djh118","article-title":"Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study","volume":"96","author":"S\u00f8rensen","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.jaad.2022.11.044_bib57","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/tri.13520","article-title":"Initial skin cancer screening for solid organ transplant recipients in the United States: delphi method development of expert consensus guidelines","volume":"32","author":"Crow","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.jaad.2022.11.044_bib58","series-title":"Prevention and Management of Skin\u00a0Cancer in Solid Organ Transplant Recipients","author":"Stasko","year":"2022"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222031450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222031450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:08:21Z","timestamp":1759273701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222031450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0190962222031450"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.044","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.043","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}